ATG-018

ATG-018 is an orally available, potent, and selective small molecule inhibitor of the ataxia telangiectasia and Rad3-related (ATR) kinase, a key protein in the DNA damage response (DDR) pathway. By inhibiting ATR kinase, ATG-018 disrupts cancer cells' ability to repair DNA damage, leading to increased accumulation of single-strand DNA breaks and potential cell death. This mechanism is particularly relevant for tumor cells with homologous recombination deficiencies or other genetic alterations affecting DDR pathways. Preclinical studies have shown efficacy as monotherapy and in combination with other DDR agents in models of solid tumors (such as gastric, esophageal, squamous cell carcinoma) and hematologic malignancies (including chronic lymphocytic leukemia [CLL], diffuse large B-cell lymphoma [DLBCL], and multiple myeloma [MM]). The drug was developed by Antengene[1][5][6].